Published on March 23, 2022, Dr. Parvin Peddi, Director of Breast Medical Oncology and Associate Professor at Saint John’s Cancer Institute, highlights the approval, which offers high-risk recurrence, breast cancer patients a new, non-chemotherapy medication that is taken annually.
“If a patient with BRCA mutation has breast cancer with high-risk features (examples are larger triple-negative breast cancers or cancer in several lymph nodes despite chemotherapy), their doctor could prescribe a year of Olaparib to increase chances of cure.”
See full article at verywellhealth.com.
FDA Approves First Treatment Targeting BRCA Mutations in Early Breast Cancer
Article by: By Alyssa Hui
March 23, 2022